# Diane Gosselin

> Diane Gosselin is a seed investor at CQDM (Montréal) backing Biotechnology and Chemical. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [CQDM](https://shizune.co/investors/profile/cqdm)
- Location: Montréal, Canada
- Total investments: 2
- Last investment: May 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/diane-gosselin-14634049/

Diane Gosselin is a seed investor at CQDM in Montréal focused on Biotechnology and Chemical. Diane Gosselin is the Chief Executive Officer at CQDM. Diane attended the College of Corporate Directors / Laval University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Chemical | 1 | 50% |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Giiant Pharma | Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M | Seed | May 21, 2021 |  |
| Encycle Therapeutics | Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation,and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein. | $840K |  | Jun 16, 2015 |  |

2 of 2 investments shown.

## Co-investors
- [Amorchem](https://shizune.co/investors/profile/amorchem) — VC Fund, 1 deal together
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 1 deal together
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund, 1 deal together
- [AQC Capital](https://shizune.co/investors/profile/anges-qu%C3%A9bec-capital) — VC Fund, 1 deal together
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 1 deal together
- [Genesys Capital](https://shizune.co/investors/profile/genesys-capital) — VC Fund, 1 deal together

## About CQDM

VC Fund · Montreal, Canada

CQDM is a drug discovery company that brings together researchers in academia, biotechs and the pharma industry.

2 contacts available at CQDM.

| Name | Title | Profile |
| --- | --- | --- |
| Diane Gosselin | Chief Executive Officer | https://shizune.co/investors/profile/diane-gosselin-519b |
| Jesse Paterson | Senior Director, Business Development | https://shizune.co/investors/profile/jesse-paterson-0b91 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Diane Gosselin invest in?

Diane Gosselin invests primarily in Biotechnology, Chemical and Biopharma startups, most often at Seed and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Diane Gosselin last invest?

The most recent investment recorded for Diane Gosselin closed in May 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co